PMID- 35237397
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220304
IS  - 2040-6207 (Print)
IS  - 2040-6215 (Electronic)
IS  - 2040-6207 (Linking)
VI  - 13
DP  - 2022
TI  - Mantle cell lymphoma management trends and novel agents: where are we going?
PG  - 20406207221080743
LID - 10.1177/20406207221080743 [doi]
LID - 20406207221080743
AB  - The heterogeneity in disease pathology, the unpredictability in disease 
      prognosis, and the variability in response to therapy make mantle cell lymphoma 
      (MCL) a focus of novel therapeutic development. MCL is characterized by 
      dysregulated expression of cyclin D1 through a chromosome t(11;14) translocation. 
      MCL international prognostic index (MIPI), ki-67 proliferation index, and TP53 
      mutation status are currently utilized for prognostication. With advances in 
      pharmacokinetic analysis and drug discovery, treatment strategy has evolved from 
      chemotherapy to combination of targeted, epigenetic, and immune therapies. In 
      this review, we discuss investigational and newly approved treatment approaches. 
      In a short time, the US Food and Drug Administration (FDA) has approved five 
      agents for the treatment of MCL: lenalidomide, an immunomodulatory agent; 
      bortezomib, a proteasome inhibitor; and ibrutinib, acalabrutinib, and 
      zanubrutinib, all Bruton kinase inhibitors. Epigenetic agents (e.g. cladribine 
      and vorinostat), mammalian target of rapamycin (mTOR) inhibitors (e.g. 
      temsirolimus and everolimus), and monoclonal antibodies and/or antibody-drug 
      conjugates (e.g. obinutuzumab, polatuzumab, and ublituximab) are promising 
      therapeutic agents currently under clinical trial investigation. Most recently, 
      chimeric antigen receptor (CAR)-T cell therapy and bispecific T-cell engager 
      (BiTE) therapy even open a new venue for MCL treatment. However, due to its 
      intricate pathology nature and high relapse incidence, there are still unmet 
      needs in developing optimal therapeutic strategies for both frontline and 
      relapsed/refractory settings. The ultimate goal is to develop innovative 
      personalized combination therapy approaches for the purpose of delivering 
      precision medicine to cure this disease.
CI  - (c) The Author(s), 2022.
FAU - Pu, Jeffrey J
AU  - Pu JJ
AUID- ORCID: 0000-0001-7498-3159
AD  - University of Arizona Cancer Center, 1515 N Campbell Avenue, Room #1968C, Tucson, 
      AZ 85724, USA.
FAU - Savani, Malvi
AU  - Savani M
AD  - University of Arizona Cancer Center, Tucson, AZ, USA.
FAU - Huang, Nick
AU  - Huang N
AD  - State University of New York Upstate Medical University, Syracuse, NY, USA.
FAU - Epner, Elliot M
AU  - Epner EM
AD  - Penn State Hershey Cancer Institute, 100 University Drive, Hershey, PA, USA.
LA  - eng
PT  - Journal Article
DEP - 20220226
PL  - England
TA  - Ther Adv Hematol
JT  - Therapeutic advances in hematology
JID - 101549589
PMC - PMC8882940
OTO - NOTNLM
OT  - BiTE therapy
OT  - CAR-T therapy
OT  - allogeneic hematopoietic stem cell transplant
OT  - cyclin D1
OT  - epigenetics
OT  - immunotherapy
OT  - mantle cell lymphoma
OT  - targeted therapies
COIS- Conflict of interest statement: The authors declare that there is no conflict of 
      interest.
EDAT- 2022/03/04 06:00
MHDA- 2022/03/04 06:01
PMCR- 2022/02/26
CRDT- 2022/03/03 05:35
PHST- 2021/11/21 00:00 [received]
PHST- 2022/01/31 00:00 [accepted]
PHST- 2022/03/03 05:35 [entrez]
PHST- 2022/03/04 06:00 [pubmed]
PHST- 2022/03/04 06:01 [medline]
PHST- 2022/02/26 00:00 [pmc-release]
AID - 10.1177_20406207221080743 [pii]
AID - 10.1177/20406207221080743 [doi]
PST - epublish
SO  - Ther Adv Hematol. 2022 Feb 26;13:20406207221080743. doi: 
      10.1177/20406207221080743. eCollection 2022.